•
Jun 30, 2020
Immunovant Q1 2021 Earnings Report
Reported financial results for the first quarter ended June 30, 2020.
Key Takeaways
Immunovant reported a net loss of $26.7 million for the quarter ended June 30, 2020, and ended the quarter with approximately $280.3 million in cash.
Research and development expenses decreased by $1.6 million compared to the same period in the prior year.
General and administrative expenses increased by $8.1 million compared to the same period in the prior year.
Net loss was $26.7 million, compared to $20.1 million for the same period in the prior year.
The company ended the quarter with approximately $280.3 million in cash.
Immunovant
Immunovant
Forward Guidance
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws.